Reimagining Vaccines for Prostate Cancer: Back to the Future

Research output: Contribution to journalReview articlepeer-review


Given the modest clinical benefits observed with immune checkpoint blockade in advanced prostate cancer, there is a renewed interest in exploring other forms of immunotherapy. Here, the authors report the use of a novel plasmid DNA vaccine encoding the androgen receptor, called pTVG-AR, in men with metastatic hormone-sensitive prostate cancer.

Original languageEnglish (US)
Pages (from-to)5056-5058
Number of pages3
JournalClinical Cancer Research
Issue number19
StatePublished - Oct 1 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Reimagining Vaccines for Prostate Cancer: Back to the Future'. Together they form a unique fingerprint.

Cite this